While emerging lines of evidence from recent studies using genetic knockdown and pharmacological inhibitors have clearly delineated the crucial role of FOXM1 in the chemoresistance of ovarian cancer [5], the role of survivin in the chemoresistance of ovarian cancer in particular remains less well characterized. This evidence concerns the gene FOXM1 and ovarian carcinoma.